2025-05 : tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member

2025-04 : tiakis Biotech AG Participates in KOL webcast on Pulmonary Arterial Hypertension (PAH)

2025-01 : tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat

2024-12 : tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients

2023-06 : First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat for Treatment of COVID-19

2023-05 : Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

2022-09 : Proteo Biotech AG becomes tiakis Biotech AG.

2022-06 : Move to a new and larger office in Kiel, Germany.

2022-01 : tiakis Biotech AG has partnered with Northway Biotech to scale up its production capabilities.

2021-12 : German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.

2021-10 : New anchor investor Elevat3 Capital joins tiakis Biotech AG.